Children's Mercy Hospital | Type 1 Diabetes TrialNet

https://www.childrensmercy.org/pediatric-endocrinology-and-diabetes/

2401 Gillham Road

Endocrine/Diabetes Office

Kansas City, MO 64108

United States

Children's Mercy Hospital is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Wayne Moore, MD, PhD the TrialNet team at Children's Mercy is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators

Wayne

Moore

MD, PhD

Dr. Moore is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City. His primary interests in diabetes research have been prevention of diabetes and its complications at a translational and clinical level. He is a Certified Physician Investigator through the Association of Clinical Research Professionals. Dr. Moore has been at Children’s Mercy Hospital for over 20 years and was at University of Kansas Medical Center prior to Children’s Mercy. MD, PhD and Pediatric Residency were completed at University of Minnesota.

Mark

Clements

MD, PhD

Dr. Clements is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City. His primary interests in diabetes research have been prevention of diabetes and its complications, and the use of big data predictive analytics to improve diabetes care. He is a Certified Physician Investigator through the Association of Clinical Research Professionals. Dr. Clements has been at Children’s Mercy Hospital for 13 years. He attended Butler University, then trained in the Medical Scientist Training Program (MD/PhD program) at Washington University in St Louis. He completed his Pediatric Residency and Endocrine/Diabetes Fellowship at Children’s Mercy Kansas City..

Lena

Huerta-Saenz

Dr. Huerta-Saenz is a pediatric endocrinologist at the Children’s Mercy Wichita specialty clinic, and Adjunct Assistant Professor of Pediatrics at the University of Missouri, Kansas City. She also has a joint appointment at the Kansas University -Wichita School of Medicine as a Clinical Assistant Professor. Dr. Huerta-Saenz, has experience monitoring clinical trials and has advanced training in “Good clinical practices”. She worked as a clinical research associate at Quintiles Transnational Inc. for 2.5 years, and performed monitoring of phase 2 &3 multicenter clinical trials before her training as a pediatrician. Dr. Huerta-Saenz also has prior experience performing site selection; site monitoring and site close out visits for clinical trials. She also received further statistic analysis training at Pontificia Universidad Catolica del Peru receiving a diploma in applied statistics.

Ryan

McDonough

DO, FAAP

Ryan McDonough, DO, FAAP is a Pediatric Endocrinologist and the Co-Medical Director of the Children’s Diabetes Center. His expertise is in the use of clinical and medical informatics to improve management of clinical trials and health care delivery, and in the care of children and adolescents with Type 1 Diabetes. His role in the Clinical Center is recruiting and assisting in prevention trials. He completed his medical school at Des Moines University in Des Moines, IA, and Pediatrics Residency and Pediatric Endocrinology & Diabetes Fellowship at Children’s Mercy.

Research Coordinators

Misty

Whisenhunt

Misty Whisenhunt is a clinical research RN coordinator at Children’s Mercy Hospital-Kansas City. Misty is responsible for screening, enrollment and monitoring visits for TN01. She is also taking part in assisting with several Trial Net prevention trials taking part at Children’s Mercy. She is new to the endocrine research group, but has been an inpatient Float Pool nurse since 2007 at Children’s Mercy.

Lois

Hester

RN, CCRC

Lois Hester, RN, CCRC is a clinical research coordinator at Children’s Mercy Hospital-Kansas City. She has been a pediatric nurse for 40 years and enjoys working with families that are dedicated to learning more about Type 1 Diabetes. She is involved with all of the TrialNet studies offered at Children’s Mercy which include prevention studies.

Darlene

Brenson-Hughes

Darlene Brenson-Hughes is the lead coordinator for the TrialNet Clinical Center at Children’s Mercy Kansas City. She is responsible for oversight of all aspects of the Pathway to Prevention program, including screening and monitoring, support of affiliate sites, and engagement with referring clinicians. She has been with Children’s Mercy since 2008

Jennifer

James

Jennifer James is a clinical research coordinator for Children's Mercy Kansas City. She is mainly responsible for the screenings and enrollment for TN01 at our College Boulevard location. She has been with Children's Mercy since 2012.

Julie

de la Garza

RN, BSN, CCRP

Julie de la Garza is a research RN coordinator at Children’s Mercy\-Wichita. Julie is responsible for screening and enrollment in TN01 in the Children’s Mercy clinic and assisting the University of Kansas Affiliate and referring physicians in Wichita and the surrounding area. She previously worked at the University of Iowa Hospitals and Clinics as the lead coordinator for Children’s Oncology Group (COG).

Jen

Bedard

BA, CCRC

Jen Bedard, CCRC is a research coordinator at Children’s Mercy Kansas City. Jen is responsible for the recruiting and enrolling for TN01 at our Northland Clinic. She has been with Children’s Mercy since 2010.

Liz

Ramey

MS, RD, LD

Liz Ramey, MS, RD, LD is a clinical trials coordinator at Children’s Mercy Hospital. Liz is responsible for the screening and enrollment visits for TN01 in multiple Kansas City area clinics. She has been with Children’s Mercy since 2016 with a Masters in Dietetics and research experience.

Aliza

Elrod

Aliza Elrod is a research database coordinator at Children’s Mercy Hospital. Aliza is responsible for quality assurance of all TN01 visits primarily making sure all source documents and consent forms are filled out completely and accurately as well as making sure the eCRF’s are entered in the TN01’s website completely and accurately. Aliza has worked with Children’s Mercy for 20 years.

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with Children's Mercy to offer convenient participation in our research programs

Columbia

University of Missouri
CRC-N508 Health Science #1, Hospital Dr, Columbia, MO 65212

Kansas City

Truman Medical Center
2411 Holmes St, SOM M4-329, Kansas City, MO 64108

Kansas City

KU Diabetes Institute - University of Kansas Medical Center
3901 Rainbow Blvd. MS 1064, Kansas City, KS 33160

Omaha

University of Nebraska Medical Center
985456 Nebraska Medical Center, Omaha, NE 68198
402.559.1193

Topeka

Cotton-O'Neil Clinical Research Center
3520 SW 6th Avenue, Topeka, KS 66606

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.

Prevention Study

Abatacept

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.

Teplizumab (Closed to Enrollment-Study Ongoing)

We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.

Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.

Longterm

Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.